Literature DB >> 2420443

Treatment of metastatic malignant melanoma with vinblastine, dacarbazine, and cisplatin: a report from the Cancer and Leukemia Group B.

R W Carey, J R Anderson, M Green, R R Ellison, L Nathanson, B J Kennedy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2420443

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Phase II trial of carboplatin in patients with advanced melanoma.

Authors:  E S Casper; D Bajorin
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.

Authors:  C Soubrane; R Mouawad; M Ichen; J Suissa; C Borel; E Vuillemin; A Benhammouda; J P Bizzari; M Weil; D Khayat
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

3.  Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.

Authors:  B Jeremic; L Djuric; L Mijatovic
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

4.  Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.

Authors:  D Pectasides; H Yianniotis; N Alevizakos; D Bafaloukos; V Barbounis; J Varthalitis; M Dimitriadis; A Athanassiou
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.